Our observations are in alignment with a recent study showing that dupilumab, a new AD drug that blocks IL4Rα, a major downstream effector of the TSLP signaling pathway, does not significantly reduce CXCL10 protein levels in human AD lesions (Hamilton et al., 2014). The gene discussed is CXCL10; the disease is Alzheimer disease.